Please login to the form below

Not currently logged in
Email:
Password:

Xceleron expands US operations

Xceleron has signed a lease on a multimillion dollar facility in the US to expand its reach in the region

UK-based drug development analytical strategies company, Xceleron, has signed a lease on a multimillion dollar facility in the state of Maryland in the US.

The facility will open in November 2007 housing a new accelerator mass spectrometer (AMS) and employing at least 20 people in scientific, commercial and administrative roles.

The move follows the establishment of Xceleron's North American business in 2005 to meet increased demand in what the company cites as a USD 1bn market worldwide for drug delivery analytics.

CEO of Xceleron, Professor Colin Garner, said: "We will invest up to USD 7.5m on the purchase of a new AMS and associated equipment to carry out analysis on pharmaceutical drug candidates. Our new facility will allow us to substantially increase our development capacity to better serve our customers worldwide."

Dr Pradeep Ganguly, director of the Montgomery County Department of Economic Development, welcomed Xceleron's decision to set up its new accelerator mass Spectrometer (AMS) in the US: "Xceleron is a highly innovative life sciences company, with a technology that will greatly advance drug discovery. We are delighted that this UK-based company has decided to expand in Germantown."

23rd July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics